The Technical Analyst
Select Language :
Silence Therapeutics plc [SLN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Silence Therapeutics plc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Silence Therapeutics plc is listed at the  Exchange

-1.01% $21.60

America/New_York / 28 mar 2024 @ 16:00


Silence Therapeutics plc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 1 004.45 mill
EPS: -1.470
P/E: -14.69
Earnings Date: May 14, 2024
SharesOutstanding: 46.50 mill
Avg Daily Volume: 0.258 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Sell
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -14.69 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.50x
Company: PE -14.69 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 20.10 - 23.10

( +/- 6.95%)
ATR Model: 14 days

Forecast: 16:00 - $21.62

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $21.62
Forecast 2: 16:00 - $21.62
Forecast 3: 16:00 - $21.62
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $21.60 (-1.01% )
Volume 0.116 mill
Avg. Vol. 0.258 mill
% of Avg. Vol 44.87 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Silence Therapeutics plc

Last 12 Months

Last 12 months chart data with high, low, open and close for Silence Therapeutics plc

RSI

Intraday RSI14 chart for Silence Therapeutics plc

Last 10 Buy & Sell Signals For SLN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$21.29N/AActive
Profile picture for
            Silence Therapeutics plc

SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Last 10 Buy Signals

Date Signal @
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978
XU100.ISMar 29 - 04:03PTS9 101.28
DYDXUSDMar 29 - 04:003.39
^KLSEMar 29 - 03:46PTS1 536.68
WSTETHUSDMar 29 - 03:594 101.01
WANETHUSDMar 29 - 03:533 523.63
KUBUSDMar 29 - 03:532.73
WTAOUSDMar 29 - 03:53524.24
NULSUSDMar 29 - 03:52$0.866

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.